Antisense & RNAi Therapeutics Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026
Report ID: GMI2487
Antisense & RNAi Therapeutics Market size is projected to experience significant growth from 2018 to 2024.
The major growth driver for the Antisense & RNAi therapeutics market is the advancement in drug delivery technology. These therapeutics are used in the treatment of rare and chronic diseases. Increase in the research and development activities to treat these diseases will play an important role in growing Antisense & RNAi therapeutics market.
Increasing successful clinical trials of the pipeline products should augment the market. The pipeline products of investigational RNAi therapeutics might be quite effective in the treatment of rare diseases like Huntington’s diseases. These positive clinical trials of therapeutic drugs will certainly influence the market growth.
Collaborations of the big pharmaceutical companies for development of these Antisense & RNAi therapeutics drugs has been a great financial driver for the growth of the market. The major players in the bio-pharma industry are enhancing the research and development areas to deliver quality products. Hence the presence of innovative product portfolio will escalate the market in the forecast period.
High cost of the product due to increasing investment in research and development activities of the Antisense & RNAi therapeutics clinical trials may be a restraining factor. Heavy investments by big pharma players in the R&D of the RNAi therapeutics market will result in increasing of the final price of the drug, narrowing the customer base. Hence this will hamper the growth of the Antisense & RNAi therapeutics market.
The Antisense & RNAi technology successfully administers the determination of role of specific genes in causing a disease. Innovation in these therapeutic technologies is the major boost for the Antisense & RNAi therapeutics market to escalate in the forthcoming years.
The Antisense & RNAi therapeutics drugs are designed to be delivered in such a way that the process will be less complex and less time consuming. Ability to deliver these therapeutic drugs in relevant concentrations to the appropriate target tissue will have a major impact on the growth of the business.
Pediatric and pre-natal population will have major impact on the Antisense & RNAi therapeutics market. This is because of the development of genetic or in-born diseases to the infants leading to disorders such as deafness, physical disabilities and other abnormalities. Increasing cases of the hereditary diseases in the new-born will help the market account for significant revenue share.
Multi-specialty hospitals and research institutes will be the major end-users for the Antisense & RNAi therapeutics products. Increasing amount of patient admissions in the hospitals for the treatment of uncommon diseases, will garner momentous amount of market in the foreseeable future.
The Antisense & RNAi therapeutic drugs have wide range of application in the fields of oncology, renal, respiratory, genetic, cardiovascular, and infectious diseases. This segment of the therapeutics market will hold a significant share due to increasing incidences of rare and chronic diseases. Oncology is one of those segments in healthcare that needs a prominent solution and treatment. So, by specifically targeting the responsible oncogenes and by inhibiting the expression of those genes, Antisense & RNAi therapeutic drugs may play a major role in the growth of the market.
U.S. will drive the Antisense & RNAi therapeutics market owing to the presence of majority of RNAi companies, coupled with investment opportunities, company assets, increasing number of clinical trials and technological advancements related to the market. Increase in number of geriatric population that suffers from acute illness to chronic diseases, cancer and cardiovascular diseases will also help the Antisense & RNAi therapeutics market grow in the North America region rapidly. Asia pacific will show significant improvement in the Antisense & RNAi therapeutics market due to increasing human population suffering from AIDS and other lifestyle diseases, focus on RNA-based development and drug discovery, advances in bioinformatics and nanotechnology.
Some of the industry players in this market include Alnylam, Mirus Bio, Marina Biotech, Benitec Biopharma, RXi pharamceuticals, Qiagen, Genzyme and Moderna. The companies are heading towards successful final stage clinical trials and new product development to grow and expand their business in this market. In March 2018, Alnylam Pharmaceuticals announced that the European Medicines Agency (EMA), granted them free passage to their Priority Medicines (PRIME), for investigating RNAi therapeutic treatment for Primary Hyperoxaluria Type 1.
Antisense & RNAi therapeutics market by technology, 2013-2024 (USD Million)
- Antisense RNA
Antisense & RNAi therapeutics market by Disease, 2013-2024 (USD Million)
- Respiratory diseases
- Infectious diseases
- Genetic disorder
Antisense & RNAi therapeutics market by delivery, 2013-2024 (USD Million)
Antisense & RNAi therapeutics market by Age group, 2013-2024 (USD Million)
- Pediatric and pre-neonatal
Antisense & RNAi therapeutics market by End-use, 2013-2024 (USD Million)
- Research institutes
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Mirus Bio
- Marina Biotech
- Benitec Biopharma
- RXi pharamceuticals
- Biogen idec
- Ionis (Roche)
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.